ArticleNature2025
Clonal driver neoantigen loss under EGFR TKI and immune selection pressures.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Personalized mRNA Neoantigen Vaccines in Cancer: Linking Precision Antigen Selection, Immune Remodeling, and Checkpoint Blockade.International journal of molecular sciences · 2026Review
- Current landscape and future directions of neoantigen vaccines: A new era of personalized cancer immunotherapy.Innovation (Cambridge (Mass.)) · 2026Review
- Pyroptosis-Amplified Decoy Nanovesicles Orchestrate Pyroptotic Antigen Explosion and Endogenous Immune Revitalization for Potentiating Tumour Immunotherapy.Journal of extracellular vesicles · 2026Article
- Immunoediting and precision biomarkers in prostate cancer: The emerging role of liquid biopsy, immune contexture and HLA genotype (Review).International journal of oncology · 2026Review
- From Universal Aspiration to Precision Immunization: A Hypothesis Framework for Antigen-Defined, HLA-Restricted Cancer Vaccines.Vaccines · 2026Review
- Cancer drug response and resistance: molecular mechanisms and combating strategies.Signal transduction and targeted therapy · 2026Review
- Should we optimise or revise the management of initially unresectable stage III non-small cell lung cancer: rethinking consolidation therapy.Journal of the National Cancer Center · 2026Article
- Charting intratumor heterogeneity from bench to bedside.Nature cancer · 2026Review
- Article
- Recurrent lung cancer with multi-organ metastases showing remarkable regression after two weeks of targeted therapy: a case report.Journal of cardiothoracic surgery · 2026Article
- A Roadmap to Transform Lung Cancer Outcomes: Priorities in Biology, Therapeutic Innovation, Early Detection, Prevention, and Interception.Cancer discovery · 2026Review
- T cell adaptation in chronic infections and tumors.Cellular & molecular immunology · 2026Review
- Integrated Single-Cell Whole-Genome Sequencing and Spatial Transcriptomics Reveal Intratumoral Heterogeneity in Ovarian Cancer.Cancer research communications · 2026Article
- Tolerance and Resistance to Targeted Therapy in NSCLC: Emerging Concepts and Strategies.JTO clinical and research reports · 2026Review
- Lung cancer vaccines to enhance immune checkpoint inhibitor therapy: evidence and future perspectives.Journal of hematology & oncology · 2026Review
- Ultrasound-driven mechanical immunomodulation enhances tumor treatment sensitivity: advances from tumor mechanical immunobiology to immunotherapy applications.Frontiers in immunology · 2026Review
- Primary and acquired resistance to immunotherapy in NSCLC.Frontiers in immunology · 2026Review
- Dynamic clonal evolution of multiple bypass resistance mechanisms inFrontiers in oncology · 2026Article
- Research on the Mechanism of "Cold Tumor" Formation and Immunotherapy for Its Transformation into "Hot Tumor".Oncology research · 2026Review
- A probabilistic and context-dependent cell culture modelling framework for regulatory toxicology.Frontiers in toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors.
Maise Al Bakir *Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0002-0846-8332
James L Reading *Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID 0000-0001-5381-978X
Samuel GamblePre-Cancer Immunology Laboratory, Research Department of Haematology, University College London Cancer Institute, London, UK.
Rachel RosenthalCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Imran UddinDivision of Infection and Immunity, University College London, London, UK.
Andrew RowanCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Joanna PrzewrockaCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Amber RogersPre-Cancer Immunology Laboratory, Research Department of Haematology, University College London Cancer Institute, London, UK.ORCID 0000-0002-7071-7889
Yien Ning Sophia WongCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Amalie K BentzenPre-Cancer Immunology Laboratory, Research Department of Haematology, University College London Cancer Institute, London, UK.
Selvaraju VeeriahCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Sophia WardCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0002-6777-5279
Aaron T GarnettInvitae Inc., Boulder, CO, USA.
Paula KalavakurInvitae Inc., Boulder, CO, USA.
Carlos Martínez-RuizCancer Genome Evolution Research Group, University College London Cancer Institute, University College London, London, UK.ORCID 0000-0002-4817-0565
Clare PuttickCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID 0009-0006-3022-8737
Ariana HuebnerCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0001-8009-4999
Daniel E CookCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0003-3347-562X
David A MooreCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0002-6296-1312
Chris AbboshCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Crispin T HileyCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Cristina Naceur-LombardelliCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID 0000-0002-7097-0307
Thomas B K WatkinsCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Marina PetkovicBerlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
Roland F SchwarzInstitute for Computational Cancer Biology (ICCB), Center for Integrated Oncology (CIO), Cancer Research Center Cologne Essen (CCCE), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Felipe Gálvez-CancinoImmune-Regulation and Immune-Interactions Laboratory, Centre for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford, Headington, UK.ORCID 0000-0001-8417-1891
Kevin LitchfieldCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0002-3725-0914
Peter MeldgaardDepartment of Oncology, Aarhus University Hospital, Aarhus, Denmark.ORCID 0000-0002-5788-4463
Boe Sandahl SorensenDepartment of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.ORCID 0000-0002-9472-8099
Line Bille MadsenDepartment of Pathology, Aarhus University Hospital, Aarhus, Denmark.
Dirk JägerDepartment of Medical Oncology, National Center for Tumor Diseases Heidelberg, Heidelberg University Hospital, Heidelberg, Germany.
Martin D ForsterCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Tobias ArkenauSarah Cannon Research Institute, London, UK.
Clara Domingo-VilaDepartment of Immunobiology, Faculty of Life Sciences and Medicine, King's College London, London, UK.
Timothy I M TreeDepartment of Immunobiology, Faculty of Life Sciences and Medicine, King's College London, London, UK.
Mohammad KadivarDepartment of Health Technology, Technical University of Denmark, Lyngby, Denmark.ORCID 0000-0003-1499-191X
Sine Reker HadrupDepartment of Health Technology, Technical University of Denmark, Lyngby, Denmark.ORCID 0000-0002-5937-4344
Benny ChainDivision of Infection and Immunity, University College London, London, UK.ORCID 0000-0002-7417-3970
Sergio A QuezadaCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. s.quezada@ucl.ac.uk.ORCID 0000-0002-9763-1700
Nicholas McGranahanCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. nicholas.mcgranahan.10@ucl.ac.uk.ORCID 0000-0001-9537-4045
Charles SwantonCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK. charles.swanton@crick.ac.uk.ORCID 0000-0002-4299-3018
Funding
Wellcome Trust CC2041
Abstract
Neoantigen vaccines are under investigation for various cancers, including epidermal growth factor receptor (EGFR)-driven lung cancers
Indexed as
Antigens, NeoplasmLung NeoplasmsProtein Kinase InhibitorsAcrylamidesAniline CompoundsCancer VaccinesClone CellsDisease ProgressionErbB ReceptorsErlotinib HydrochlorideFemaleHumansIndolesLiver NeoplasmsMaleMutationAcrylamidesAniline CompoundsAntigens, NeoplasmCancer VaccinesEGFR protein, humanErbB ReceptorsErlotinib HydrochlorideIndolesosimertinibProtein Kinase InhibitorsPyrimidines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.